Treatment of acquired perforant dermatoses with allopurinol

Tratamento de dermatose perfurante adquirida com alopurinol

Naomi Carrara Matsuura¹, Fernanda Pereira¹, Lissa Nakazato¹, Luana Rocco Pereira Copi¹

ABSTRACT

Perforating dermatoses are papulonodular cutaneous pathologies characterized by transepithelial extrusion of components of the extracellular matrix of the dermis, by inflammation or degeneration. When secondary, the systemic diseases are called Acquired Perforating Diseases. Our letter aims to report a case of acquired perforating dermatoses secondary to chronic renal dialysis. The treatment with Allopurinol proved to be effective in this case. Allopurinol would act as an antioxidant, reducing the inflammatory reaction in tissues and consequent damage to the collagen fibers.

Keywords: Allopurinol, Chronic Renal Insufficiency, Prurigo.

RESUMO

Dermatoses perfurantes são patologias cutâneas papulonodulares que se caracterizam pela extrusão transepitelial de componentes da matriz extracelular da derme, por inflamação ou degeneração. Quando são secundárias as doenças sistêmicas são chamadas Doenças Perfurantes Adquiridas. Nossa carta tem como objetivo relatar caso de dermatose perfurante adquirida secundária a insuficiência renal crônica dialítica. O tratamento com Alopurinol se mostrou eficaz neste caso. O Alopurinol atuaria como antioxidante, reduzindo a reação inflamatória nos tecidos e consequentes danos nas fibras colágenas.


1. College of Medicine CERES, São José do Rio Preto, (SP) Brazil.
Perforating dermatoses are papulonodular cutaneous pathologies that are characterized by transepithelial extrusion of components of the extracellular dermal matrix, by inflammation or degeneration. Perforating diseases are classified into primary or hereditary and secondary or acquired. Acquired Perforating Disease (APD) is a clinicopathological entity that is associated with systemic diseases. The most prevalent symptoms of APD are pain and itching, with frequent bruising and crusting. Koebner’s phenomenon occurs in 31% of the cases. The lesions are characterized by plaques, papules or nodules of 4 to 10 mm, which umbilicate in 3 to 5 weeks and regress in 6 to 8 weeks, forming an adherent keratotic buffer, and subsequent evolution to scarring or residual hyperchromia. The lesions are located predominantly on the extensor surfaces of the limbs and the trunk and head, being more frequent the multiple localization. The diagnosis is clinical and histopathological, implying compliance to Fayer criteria: histopathology with transepidermic elimination of basophilic necrotic collagen fibers in an epidermal depression in the form of cups, papules or umbilicated nodules with an adherent keratotic center, and beginning after the age of 18 years. The differential diagnosis includes other perforating diseases, the nodular prurigo and hypertrophic lichen planus. A female patient, 58-year-old, with dialytic chronic renal failure by Multiple Myeloma, presented the appearance of erythematous-violaceous papules, pruritic umbilicates in the trunk region and limbs (Figure 1). Performed incisional biopsy compatible with APD (figure 2). It was initiated treatment with topical corticosteroids and antihistamines, phototherapy, topical retinoids and cryotherapy. The use of Allopurinol has been described as a new possibility of treatment in use isolated or associated with PUVA (Psoralen and ultraviolet radiation). The mechanism of action could be explained by the inhibition of Allopurinol in the xanthine oxidase enzyme. This enzyme is responsible for catalyzing the oxidation of hypoxanthine to xanthine, forming during this reaction reactive oxygen species. These molecules are highly reactive due to their oxidative properties and can act directly on the lipid components of cell membranes, culminating in a destructive effect on the cell. Thus Allopurinol would act by decreasing oxygen radicals that cause collagen damage. A previous study demonstrated the efficacy of Allopurinol in the treatment of APD, using the initial dose of 100 mg per day oral, observed an improvement in seven patients in a period of 4-weeks, and in five patients within 2 to 4 months. In the reported case, Allopurinol was effective in APD treatment in double doses with results in 3 to 4 weeks, without recurrence of lesions during the patient follow-up. There were no adverse effects reported. It was concluded that Allopurinol was effective for the treatment of APD triggered by chronic dialytic renal failure, acting as an antioxidant, reducing the inflammatory reaction in tissues and consequent damage to the collagen fibers.
ILLUSTRATION

Figure 1. Umbilicated erythematous-violaceous papules in lower limbs and gluteus

Figure 2. Hematoxylin & eosin, 100x Calcified basophilic collagen fibers

Figure 3. Resolution of the picture after treatment with Allopurinol

BIBLIOGRAPHIC REFERENCES


